Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)’s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $51.00 target price on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 90.80% from the stock’s current price.
Other equities research analysts have also issued research reports about the company. Cantor Fitzgerald reissued an “overweight” rating and set a $54.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, August 22nd. Wells Fargo & Company upped their price objective on shares of Arcturus Therapeutics from $35.00 to $45.00 in a research report on Monday, July 17th. William Blair started coverage on shares of Arcturus Therapeutics in a research note on Monday, July 24th. They issued an “outperform” rating and a $71.00 target price on the stock. Guggenheim reissued a “buy” rating on shares of Arcturus Therapeutics in a research note on Friday, July 14th. Finally, StockNews.com assumed coverage on shares of Arcturus Therapeutics in a research report on Thursday, August 17th. They set a “hold” rating on the stock. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $38.78.
Arcturus Therapeutics Trading Up 1.8 %
Arcturus Therapeutics stock opened at $26.73 on Wednesday. The firm has a 50 day simple moving average of $30.92 and a 200 day simple moving average of $27.75. Arcturus Therapeutics has a 1-year low of $13.54 and a 1-year high of $37.75. The firm has a market capitalization of $711.02 million, a price-to-earnings ratio of 9.25 and a beta of 2.64.
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.98) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($2.07). Arcturus Therapeutics had a net margin of 30.36% and a return on equity of 20.75%. The company had revenue of $10.52 million for the quarter, compared to the consensus estimate of $71.05 million. On average, equities research analysts forecast that Arcturus Therapeutics will post -3.56 EPS for the current year.
Insider Transactions at Arcturus Therapeutics
In related news, insider Keith C. Kummerfeld sold 6,968 shares of the firm’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $35.00, for a total value of $243,880.00. Following the sale, the insider now directly owns 950 shares of the company’s stock, valued at $33,250. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Arcturus Therapeutics news, insider Keith C. Kummerfeld sold 6,968 shares of the company’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $35.00, for a total transaction of $243,880.00. Following the transaction, the insider now owns 950 shares in the company, valued at approximately $33,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Pad Chivukula sold 5,000 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $28.75, for a total value of $143,750.00. Following the transaction, the chief operating officer now directly owns 544,448 shares of the company’s stock, valued at approximately $15,652,880. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,968 shares of company stock worth $1,420,130. Company insiders own 13.80% of the company’s stock.
Institutional Trading of Arcturus Therapeutics
Several institutional investors have recently bought and sold shares of the company. HRT Financial LP bought a new stake in Arcturus Therapeutics in the 4th quarter worth about $1,025,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Arcturus Therapeutics in the first quarter valued at about $212,000. New York Life Investment Management LLC boosted its stake in Arcturus Therapeutics by 12.7% in the 4th quarter. New York Life Investment Management LLC now owns 21,040 shares of the biotechnology company’s stock worth $357,000 after purchasing an additional 2,371 shares during the period. Daiwa Securities Group Inc. increased its holdings in Arcturus Therapeutics by 23.8% in the 1st quarter. Daiwa Securities Group Inc. now owns 4,109 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 789 shares during the last quarter. Finally, Jump Financial LLC increased its holdings in shares of Arcturus Therapeutics by 103.8% in the first quarter. Jump Financial LLC now owns 41,741 shares of the biotechnology company’s stock worth $1,001,000 after purchasing an additional 21,263 shares during the last quarter. 88.87% of the stock is owned by hedge funds and other institutional investors.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.